325 research outputs found
Intravascular lymphoma presenting as a specific pulmonary embolism and acute respiratory failure: a case report
This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens
Pulmonary intravascular lymphoma diagnosed by 18-fluorodeoxyglucose positron emission tomography-guided transbronchial lung biopsy in a man with long-term survival: a case report
<p>Abstract</p> <p>Introduction</p> <p>18-Fluorodeoxyglucose positron emission tomography can detect the pulmonary involvement of intravascular lymphoma that presents no abnormality in a computed tomography scan.</p> <p>Case presentation</p> <p>We report the case of a 61-year-old Japanese man who had pulmonary intravascular lymphoma and no computed tomography abnormality. We were able to make an antemortem diagnosis of pulmonary intravascular lymphoma by transbronchial lung biopsy according to 18-fluorodeoxyglucose positron emission tomography findings. He is free of recurrent disease 24 months after chemotherapy.</p> <p>Conclusions</p> <p>To the best of our knowledge, this is the first reported case of a long-term survivor of pulmonary intravascular lymphoma diagnosed by transbronchial lung biopsy under the guide of 18-fluorodeoxyglucose positron emission tomography.</p
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.
Background: Deletions at 13q14.3 are common in chronic lymphocytic leukemia and are also present in diffuse
large B-cell lymphomas (DLBCL) but never in immunodeficiency-related DLBCL. To characterize DLBCL with 13q14.3
deletions, we combined genome-wide DNA profiling, gene expression and clinical data in a large DLBCL series treated
with rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 days (R-CHOP21).
Patients and methods: Affymetrix GeneChip Human Mapping 250K NspI and U133 plus 2.0 gene were used.
MicroRNA (miRNA) expression was studied were by real-time PCR. Median follow-up of patients was 4.9 years.
Results: Deletions at 13q14.3, comprising DLEU2/MIR15A/MIR16, occurred in 22/166 (13%) cases. The deletion
was wider, including also RB1, in 19/22 cases. Samples with del(13q14.3) had concomitant specific aberrations. No
reduced MIR15A/MIR16 expression was observed, but 172 transcripts were significantly differential expressed.
Among the deregulated genes, there were RB1 and FAS, both commonly deleted at genomic level. No differences in
outcome were observed in patients treated with R-CHOP21.
Conclusions: Cases with 13q14.3 deletions appear as group of DLBCL characterized by common genetic and
biologic features. Deletions at 13q14.3 might contribute to DLBCL pathogenesis by two mechanisms: deregulating the
cell cycle control mainly due RB1 loss and contributing to immune escape, due to FAS down-regulation
Primary brain T-cell lymphoma of the lymphoblastic type presenting as altered mental status
The authors present a case of a 56-year-old man with altered mental status. Magnetic resonance imaging (MRI) of the brain revealed non-enhancing abnormalities on T2 and FLAIR imaging in the brainstem, cerebellum, and cerebrum. Immunohistochemisty demonstrated precursor T-cell lymphoblastic lymphoma. After treatment with methotrexate, he improved clinically without focal sensorimotor deficits and with improving orientation. MRI showed almost complete resolution of brainstem and cerebral lesions. To the authors’ knowledge, there are only five previous reports of primary central nervous system T-cell lymphoblastic lymphoma. Since treatable, it deserves consideration in patients with altered mental status and imaging abnormalities that include diffuse, non-enhancing changes with increased signal on T2-weighted images
- …